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nloadedMembrane-bound pyrophosphatases are homodimeric integral membrane proteins that hydrolyze pyrophosphate
into orthophosphates, coupled to the active transport of protons or sodium ions across membranes. They are im-
portant in the life cycle of bacteria, archaea, plants, and parasitic protists, but no homologous proteins exist in ver-
tebrates, making them a promising drug target. Here, we report the first nonphosphorus allosteric inhibitor of the
thermophilic bacterium Thermotoga maritima membrane-bound pyrophosphatase and its bound structure
together with the substrate analog imidodiphosphate. The unit cell contains two protein homodimers, each binding
a single inhibitor dimer near the exit channel, creating a hydrophobic clamp that inhibits themovement of b-strand
1–2 during pumping, and thus prevents the hydrophobic gate from opening. This asymmetry of inhibitor binding
with respect to each homodimer provides the first clear structural demonstration of asymmetry in the catalytic cycle
of membrane-bound pyrophosphatases. fro
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 INTRODUCTION
Membrane-bound pyrophosphatases (mPPases) are a family of en-
zymes that hydrolyze pyrophosphate into two phosphates and cou-
ple this reaction with proton and/or sodium transport across the
membrane, creating an electrochemical gradient. These enzymes,
initially discovered in photosynthetic bacteria and plants (1–3) and
later found in parasitic protists, archaea, and certain species of bacteria,
do not occur in animals and humans (4, 5). In various organisms,
mPPases are important for survival under diverse stress situations
due to energy limitation, such as osmotic stress, anoxia, mineral defi-
ciency, low temperature, and intense light (6). In bacteria and archaea,
mPPases reside in the cell membrane (4), while in protists, algae, and
plants, they can also be located in acidocalcisomes, the vacuole, and/or
Golgi apparatus (7, 8).
mPPases are homodimeric. Eachmonomer contains 15 to 17 trans-
membrane helices (TMHs) with a molecular weight of 70 to 81 kDa. So
far, there are structures from just two mPPases: four of Thermotoga
maritima (TmPPase) and two of mung bean (Vigna radiata: VrPPase).
TmPPase structures are available in the resting state (TmPPase:Ca:Mg)
(9), with two phosphates bound (TmPPase:2Pi) (9), with the substrate-
analog imidodiphosphate (IDP) bound (TmPPase:IDP) (10), and with
the phosphate analog (WO4) bound (TmPPase:WO4) (10). VrPPase has
been solved in the IDP-bound (VrPPase:IDP) (11) and single phosphate-
bound states (VrPPase:Pi) (10). In all these structures, mPPase is a sym-
metric homodimer, with each monomer consisting of 16 TMHs. These
helices form two concentric layers, with 6 helices (TMH5, TMH6,
TMH11, TMH12, TMH15, and TMH16) forming the inner layer
and the other 10 (TMH1 to TMH4, TMH7 to TMH10, TMH13, andTMH14) forming the outer layer. Each monomer consists of four
regions: a hydrolytic center, a coupling funnel, an ion gate, and an
exit channel (Fig. 1A) (12). The hydrolytic center and coupling fun-
nel are composed of TMH5, TMH6, TMH11, TMH12, TMH15, and
TMH16 (Fig. 1B). Upon substrate binding, the active site is closed by
a long loop between TMH5 and TMH6 and opened again after hy-
drolysis and ion pumping (9–11). In the structure of TmPPase:IDP,
Na+ binds within the membrane plane at the ionic gate between
TMH6 and TMH16. Na+ is pentacoordinated by the carboxylate
groups of D2436.50, E2466.53, and D70316.46, by the OU of S2476.54,
and with the main-chain carbonyl of D2436.50 (Fig. 1C) (10). [Resi-
dues are numbered as in (12), shown as XSa.b, where X is the amino
acid, S is amino acid position in TmPPase, a is the helix number, and
b is the amino acid position according to a central conserved residue
in each helix.]
Parasitic protists such as Plasmodium falciparum, Toxoplasma
gondii, Trypanosoma brucei, and Leishmania donovani all have H+-
pumping mPPases (13) of two different types (K+ dependent and K+
independent) in Plasmodium (14) and of just one type (K+ dependent)
in the others (15–17). The mPPases, along with a V–adenosine tri-
phosphatase, maintain the ionic gradient across the acidocalcisome
membrane, which is necessary for acidocalcisome function, such as os-
motic homeostasis upon passage of the parasite from the insect vector
into the mammalian bloodstream (8). Knockdown/knockout of
mPPases causes severe reduction in polyphosphate and the loss of
acidocalcisome acidity, leading to the failure of the parasites to sta-
bilize their intracellular pH upon exposure to external basic pH (18).
In addition, it has been shown that mPPase is essential for virulence
of T. gondii in a mouse model (19). mPPases are thus promising tar-
gets for structure-based drug design because they are essential and
do not exist in multicellular animals and structures in different con-
formations are known.
Nonhydrolyzable PPi analogs are not viable mPPase drug candi-
dates, as they will inhibit the many human enzymes that produce or
hydrolyze PPi, from inorganic pyrophosphatases to polymerases and
ectonucleotide pyrophosphatases/phosphodiesterases (20). Our goal1 of 12
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 is thus the discovery of drug-like small molecular weight compounds
that would specifically inhibit mPPases from parasitic protists (13).
Here, we report the discovery and synthesis of the first nonphosphorus,
non–substrate-analog inhibitor of TmPPase, N-[(2-amino-6-
benzothiazolyl)methyl]-1H-indole-2-carboxamide (ATC), its pre-
liminary structure-activity relationships (SARs), and a 3.4 to 4.0 Å
resolution structure of ATC bound to TmPPase. It inhibits TmPPase
with lowmicromolar affinity. The binding site of ATC is allosteric and
furthermore asymmetric with respect to the structural homodimer,
providing strong evidence that the substrate binding and catalysis
events proceed asymmetrically.19RESULTS
Structure overview
We solved the 3.4 to 4.0 Å resolution of the TmPPase structure in
complexwith IDP andATC (TmPPase:IDP:ATC) bymolecular repla-
cement using the TmPPase:IDP structure [Protein Data Bank (PDB)
ID: 5LZQ] (10) as the search model but with the IDP removed. [We
quote two numbers for the resolution, as the data are quite anisotropic,
as shown by the STARANISO server (http://staraniso.globalphasing.
org) with a maximum resolution of 3.6 Å along the a* axis, 3.4 along
c*, but slightly worse than 4.0 Å along b* (table S1); we followed cur-
rent best practice and used all of the data above a local I/s(I) cutoff of 3
(21).] Molecular replacement identified four TmPPasemolecules (two
dimers) in the asymmetric unit. After the first round of refinement, we
observed positive (Fo-Fc) density at 3.0 s at the hydrolytic center (fig.
S1A) in all four chains and at the ionic gate (fig. S1B) in chains A, B,
and D. We built the Mg5IDP complex into the former and a sodium
ion into the latter. Therewas positive (Fo-Fc) density between atomO3
of IDP and A495 in chains A, B, and D after placement of theMg5IDPVidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019complex. We fit K+ into the density (fig. S1A) as this is its known
binding site (11).
We also observed positive 3.0 s (Fo-Fc) density that was shaped
like two connected pancakes near the exit channels of chains A and
C. Fitting the density near chain A with ATC in combination with
different ions and water molecules (fig. S1, E to J) showed that it was
best described as two ATC molecules in a head-to-tail orientation
(Fig. 2A and fig. S1E). These ATCs (ATC-1 and ATC-2) are located
at the interface between chains A andD (Fig. 2A). However, only one
ATC (ATC-3) could be located at the interface between chains B and
C as the density in these chains was weaker. After refinement, man-
ual rebuilding, and manual placement of the IDP and ATC into the
electron density, we were able to refine it to an Rwork/Rfree of 22.8%/
28.4% with acceptable stereochemistry (table S1). Unlike previously
solved TmPPase structures (9, 10), there are four molecules (two di-
mers, AB and CD) in the asymmetric unit (fig. S2A). The root mean
square deviation (RMSD) per Ca is 0.31 Å2 for the AB dimer versus
the CD dimer and 0.26 to 0.33 Å2 when comparing individual mono-
mers (table S2).
There are thus two dimer interfaces in the crystal structure: the AB
interface described before (9, 10) and ATC-mediated AD and BC di-
mers (fig. S2). Are these latter dimers physiologically relevant? It is
fairly clear that the answer is no. First, the interactions are weak for a
protein interface (249Å2 buried) and the proteins interact tail to tail (fig.
S2B), placing the extracellular loops together in a manner that would
not allow a bilayer to form. Second, size exclusion chromatography–
multiangle laser light scattering (SEC-MALLS) analysis showed that
the addition of ATC to the TmPPase:IDP complex (158.9 ± 0.1 kDa)
did not change the oligomerization state of the protein (162.8 ± 3.7 kDa
for the TmPPase:IDP:ATC complex) (fig. S3). The ATC pair binding
near A interacts structurally as a dimer. In the “Kinetics of ATCHydrolytic
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Fig. 1. Overview of the TmPPase structure. (A) Monomer showing the location of the hydrolytic center, coupling channel, ion gate, and exit channel. (B) Top view of the
superpositionof the TmPPase:IDP:ATC (wheat) and TmPPase:IDP complex (cyan) structure showing relative TMHmovements (arrow) uponbinding ofATC. (C) Superposition of
the gate region between two structures [TmPPase:IDP:ATC (wheat) and TmPPase:IDP complex (cyan)]. D2466.53, D70316.46, and Na+ slightly moving away (arrow) relative to
their positions in the TmPPase:IDP structure. Violet-purple and pink spheres are for Na+ of TmPPase:IDP and TmPPase:IDP:ATC, respectively.2 of 12
SC I ENCE ADVANCES | R E S EARCH ART I C L E
 o
n
 June 17, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 binding” section, we show that ATC binds functionally as a dimer to
both the E2S and E2S2 complexes in solution.
The overall structure of the TmPPase:IDP:ATC complex is very
similar to that of the TmPPase:IDP complex, with an RMSD/Ca of
0.50 and 0.43 Å to dimers AB and CD, respectively. (In what follows,
all structural alignmentsweremadewith respect tomonomerA unless
otherwise stated.) Although the volume of the hydrolytic pocket in
TmPPase:IDP:ATC is very similar to that of TmPPase:IDP (707 Å3
versus 720 Å3), on the basis of the structural alignment on TMH13
and TMH14 (residues 542 to 629), there are slight clockwise move-
ments on the cytoplasmic side of the protein helices relative to the
TmPPase:IDP structure (Fig. 1B). This causes a slight movement of
the Mg5IDP complex in the same direction as the helices. In addition,
at the gate of the TmPPase:IDP:ATC structure, Na+ is pentacoordinated
byD2436.50, E2466.53, S2476.54, andD70316.46 (bidentate to both carbox-
ylate oxygens) (Fig. 1C). In TmPPase:IDP, the coordinating residues are
D2436.50 (side chain and main chain), E2466.53, S2476.54, and D70316.46,
and the D2436.50 C=O—Na+ distance is 2.8 Å versus the considerably
longer 4.0 Å in TmPPase:IDP:ATC. This is mostly because the sodium
ion appears to be translated by about ~1.7 Å. We believe that these
structural changes are functionally significant and related to the binding
of ATC (see the “Asymmetry” section below).
ATC binds in a cleft beside the exit channel
During refinement, we observed extra density near chains A and D
(Fig. 2A), where we were able to model ATC. ATC is a rigid multiring
system with only two free torsion angles, which we modeled in trans
geometry, themost prevalent in the solution [SupplementaryMaterials,
nuclear magnetic resonance (NMR) spectra]. We could thus (Fig. 2A)
place two molecules of ATC into the (Fo-Fc) electron density map.
There is (Fo-Fc) density in an equivalent region near chains B and C,
where a single ATC could be fitted, but the density there is too poor to
fit an ATC dimer, presumably due to molecular disorder in the crystal.
We thus focus onATC-1 andATC-2, which bind to chains A andD, as
representing the TmPPase2(Mg5PPi)2(ATC2)1 complex, where the
ATC dimer binds asymmetrically to TmPPase.
Two molecules of ATC p-stack head to tail (Fig. 2 and fig. S1D)
and bind in a hydrophobic cleft. The cleft is formed by strands b1–2
(loop6–7), loop8–9, and loop12–13, near the exit channel of chain A,
with loop2–3 and loop4–5 on chain D (Fig. 3A). (A similar cleft forms
between chains B andC.) In termsof buried surface area,ATC-1buries
112Å2 on chainA and 85Å2 on chainD, while ATC-2 buries 85Å2 on
chain A and 92 Å2 on chain D (table S3).Vidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019ATChas a 2-aminothiazole group, which is a weak base [pKa (where
Ka is the acid dissociation constant), 4.23 ± 0.03; (22)] reported in both
neutral and protonated forms in the PDB and CSD (Cambridge Struc-
turalDatabase).Wemodeled the 2-aminothiazole groups in the proton-
ated state because both ATCs in the AD interface form ion pairs/
hydrogen bonds with chain A (Fig. 2B and table S3). Chain A Q268
seems to be the key interacting residue. It forms H bonds to both N11
and N12 of ATC-2, and to O01 of ATC-1 (see fig. S1D for atom
numbering of ATC), suggesting how the ATC dimer is stabilized on
the enzyme. Chain A D351 (Od1) forms a salt bridge with 2-amino-
thiazole on ATC-2 (Fig. 2B and table S3). In chain D, on the other
hand, the chief interactions do not seem as strong: A single hydrogen
bond is formed between ATC-2N19 and N157 Od1, and the remain-
ing interactions are the hydrophobic stacking ofW164 onATC-1, and
the indole of ATC-2 sandwiched between W74 andW164 and stack-
ing onY161 (Fig. 2C and table S3). These interactionswith chainD are
probably due to crystal packing, as the binding of ATC to the protein
did not change the protein oligomerization in the solution (fig. S3).
We therefore focus on the interactions of the ATCdimerwith chainA.
Asymmetry
Artukka and co-workers (23) recently demonstrated functional
asymmetry in K+-dependent mPPases in the presence of excess po-
tassium ion. Here, we show the first structural evidence of asymmetry.
The IDP-bound state has the most symmetrical structure (the lowest
RMSD values) between each monomer compared to others (table S4
and fig. S4A). However, the binding of ATC makes the IDP-bound
enzyme asymmetric, especially in the loops that interact with the in-
hibitor (loop8–9, b1–2, and loop12–13): The RMSDbetween the b1–2
loop in chain A (ATC bound) and chain B (no ATC) is 1.25 Å (table
S4). Structural alignment between monomers of other states (the
resting state, 2Pi-bound state, and WO4
2− bound state) shows that
these loops differ far less (table S4). In addition, there is a change in
the binding mode of Na+ at the ionic gate (see above).
ATC binds as a dimer in chain A, holding the b1–2 loop (Q268,
K269, I270, and Q277), loop8–9 (D351 and V352), and loop12–13
(P530) together (Fig. 3A and fig. S4, B and C). Comparison of the
structure of the loops interacting with ATC with the equivalent loops
in TmPPase:IDP showed that the loops b1–2 and 12–13 in chain A
move the most, with an RMSD per Ca of 1.13 and 1.09 Å, respectively
(table S5), because these loops interact with the ATC dimer (Fig. 3B
and table S3). In contrast, the RMSDs/Ca for the other loops that in-
teract with ATC is smaller (table S5). Comparing all the TmPPaseY161
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Fig. 2. ATC interactions with TmPPase domains. (A) ATC [positive (Fo-Fc) electron density map at 3s] located on the interface of chains A (wheat) and D (gray) in a
hydrophobic cleft. Pale green, carbon; blue, nitrogen; red, oxygen; yellow, sulfur. (B) Residues in chain A that are important for the interactions with the ATC dimer. The
closest approach of the two ATC molecules is 3.3 Å, consistent with p-p stacking. (C) Residues on chain D that are important for the interactions with the ATC dimer.
Dashed lines represent hydrogen bonds.3 of 12
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 states shows that the binding of ATC causes the b1–2 strand of chain
A to move away from the dimer interface relative to its position in
TmPPase:IDP and TmPPase:2Pi to roughly the same angle as in the
resting and Pi structures (Fig. 3C, inset bottom view; periplasmic
side)—when the exit channel must remain closed at all times. The
movement of chain A b1–2 due to the binding of the ATC dimer thus
creates a hydrophobic clamp that locks the TmPPase exit channel in
a closed state after substrate binding. In contrast, it appears that ATC
does not bind to chain B because the b1–2 strand has moved away
from loop12–13, closer to its position in the resting state (table S4
and fig. S5), and has become disordered. ATC appears not to bind
because Q268 and Q277, key elements in the binding site, have be-
come disordered. The same disordering, and lack of binding of ATC,
is seen in monomer D.
Pharmacology of ATC and analogs at TmPPase
We synthesized not only ATC but also four analogs (compounds 2,
3, 4, and 5) (Fig. 4A) with different ring structures. Four other ana-
logs (compounds 6, 7, 8, and 9), three of them brominated, were also
designed for structural studies. The median inhibitory concentra-Vidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019tions (IC50s) of all the compounds were at least 20 times worse than
the original hit ATC (Fig. 4, B and C), and they did not help us solve
the structure. They do, however, provide initial SARs for this family
of compounds on TmPPase.
The suggested binding mode explains the SARs of the ATC ana-
logs (Fig. 4). First, they show that the hydrogen bonding functional-
ity of the indole ring is important; compounds 2 and 3 that lack this
functionality are inactive. In the TmPPase:IDP:ATC structure, Q268
near the indole nitrogen of ATC explains not only the lack of activity
of compounds 2 and 3 but also the tolerance of both hydrogen bond
donor (nitrogen; compound 5) and acceptor (oxygen; compound 4)
functionalities in this position. Second, the aromatic nature of the
indole ring seems important for activity: Compounds 4 and 5 that
include suitable hydrogen bonding functional groups but not a bulky
ring structure are approximately 10-fold less active than ATC. The
indole rings of ATC-1 and ATC-2 form p-p stacking interactions
with each other: Removing the benzene ring weakens this interac-
tion. Third, compounds 6, 7, and 8 with bromine substitutions are
10- to 100-fold weaker binders than ATC, suggesting the importance
of the unsubstituted indole ring. The bromine substitutions mayA B
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Fig. 3. Loop movement caused by the interactions with ATC. (A) ATC dimer interaction with b1–2 strand (deep blue), loop8–9 (red), and loop12–13 (cyan). ATC is
depicted in space-filling model (pale green, carbon; blue, nitrogen; red, oxygen: yellow, sulfur). (B) Superposition of TmPPase:IDP (cyan) with the TmPPase:IDP:ATC
structure (wheat) and TmPPase:Ca:Mg (green) showing the large side movement of b1–2 strand (arrow). ATC is depicted as in (A). (C) Superposition of TmPPase
structures in all different states showing the closer/away movement of b1–2 strand relative to the loop12–13 and the dimer interface of the protein. Coloring scheme
from left to right: pink, phosphate analog (WO4)–bound state (TmPPase: WO4); green, resting state (TmPPase:Ca:Mg); orange, two-product–bound state (TmPPase:2Pi);
cyan, IDP-bound state (TmPPase:IDP); wheat, IDP:ATC-bound state (TmPPase:IDP:ATC). (D) Superposition of TmPPase structures showing the downward movement of
TMH12 and away movement of loop12–13 from the resting state (green) to the IDP:ATC-bound form (wheat) of TmPPase. The green-to-wheat colored arrow shows
the movement.4 of 12
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 weaken the p-p stacking interactions by altering the shape and loca-
tion of the p-electron cloud. However, there are also direct clashes
with loop6–7 and loop12–13, which are key sites of interaction
(see above). In particular, the weakest brominated compound 8
would clash with P530 in loop12–13 (ATC C08-P530: 3.1 to 3.3 Å),
while brominated compound 7 would clash with the K269 side chain
(ATC C06-K269: 3.8 Å). Last, benzimidazole substitution instead of
an indole yields fully inactive compound 9. This is probably due to
the loss of the p-p head-to-tail stacking: Both the 2-aminothiazole
and the benzimidazole groups are protonated at physiological pH,
so they would repel each other.
Kinetics of ATC binding
As ATC is a potent inhibitor, we further characterized its effect on the
rate of substrate (PPi) hydrolysis using a range of ATC concentrations
(0.0 to 12.0 mM).We performed the kinetic assay using PPi concentra-Vidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019tions from 0 to 1714 mM at 71°C with a single-point measurement at
2 min (Fig. 4D), having shown that this is within the linear range for
initial rates (fig. S7). The shape of these curves was unexpected, so we
performed a Hill analysis (Fig. 4E and table S6), which showed that,
at substrate concentrations greater than 100 mM (i.e., when the sub-
strate is bound; see below), the Hill coefficient for ATC binding is 2.
We therefore performed a simultaneous analysis of the data for all
inhibitor and substrate concentrations using the model in Fig. 5 with
Eq. 1 and n = 2 (Table 1), with the exception thatKI1
2 is not fit (when
we included it, the residuals did not improve, and its mean value is
≥0.25 mM; data not shown) (Fig. 4D). Themodel is a variant on that
used by Artukka et al. (23) and is required as there is half-of-the-sites
reactivity. The sumof squares when fitting the inhibition curves with an
ATCmonomer (i.e., n = 1 in Fig. 5) is 5268, and the SD of the residuals
(Sy.x) is 4.3; when fitting an ATC dimer, the values are 855 and 1.8,
respectively. The model shown (Figs. 4D and 5) is the simplest that fitsA
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 the data: Othermodels do not fit (data not shown).We did not endeavor
to fit sequential binding of ATC to the TmPPase dimer as the data are
insufficient for the purpose. This means that ATC binds as a dimer to
TmPPase.ATCbinds tightest to theE2S complex (KI2obs=1.37±0.09mM):
Its binding to E2S2 is about 2.5-fold weaker (KI3obs = 3.18 ± 0.15 mM),
and it does not bind toE2 at concentrationswe are able to achieve (Table 1).
ATC is thus an uncompetitive dimeric inhibitor with a clear preference
for binding to the single-substrate bound form.
Our data also show that, after one monomer binds the substrate
to form the E2S complex, the other monomer binds the substrate
much more tightly: The value of a is very low (0.12) (Table 1). How-
ever, the hydrolysis rate of the E2S2 complex is 20-fold slower
(b = 0.05) compared to the E2S complex (kp = 234.5 ± 27.1 mmol
Pi mg
–1 min–1) (Table 1). In comparison with earlier reports (23),
the binding behavior is different but the ratio of hydrolysis rates is
similar (see Discussion). In the crystal structure we solved, ATC is
bound to the E2S2 form, not to the E2S form. The concentration of
ATC added for crystallization (1 mM) was higher than the binding
constant of ATC to the E2S2 form (Table 1), and ATC binding to the
E2S formmay induce a conformational change in the other monomer
that allows further substrate binding (see Discussion). This is con-
sistent with the fact that we could only crystallize the TmPPase:ATCVidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019complex in the presence of IDP. ATC is thus the first nonphosphorus
inhibitor and the first allosteric inhibitor identified for mPPase.
Is ATC a viable lead against parasitic mPPases?
ATC would be a potential lead as an antiparasitic agent if it were ac-
tive against parasitic protists such as Plasmodium spp. Preliminary
studies with isolated P. falciparummembranes showed that ATC had
an IC50 of around 80 mΜ (fig. S6A), i.e., at least 40-fold lower than in
our test system T. maritima (Fig. 4A). In the P. falciparum survival
assays, ATC did not show any anti-plasmodial activity (fig. S6B).
On the other hand, knockout of mPPases inT. gondii (19) andT. brucei
(24) demonstrate that functional mPPase is required for survival and
virulence of these parasites.
To explain these findings and study the potential specificity deter-
minants at the binding sites of ATC-1 and ATC-2 across mPPases, we
retrieved the sequences of 16mPPases fromparasitic protists as well as
representatives of all the other mPPase families (fig. S8). The areas
corresponding to loop6–7 (i.e., b1–2 strand), loop8–9, and loop12–13
showed a high degree of difference between TmPPase and the other
mPPases (Fig. 6A and fig. S8). In particular, b1–2 (loop6–7) is missing
in parasite mPPases. As the binding site of ATC-1 and ATC-2 is lo-
cated on these loops (6–7, 8–9, and 12–13 of chain A), ATC could not
bind themPPases of pathogenic parasites as it does TmPPase. To val-
idate this finding, we built a homology model of P. falciparum
mPPase (PfPPase; Fig. 6B). Loop6–7 and loop12–13 of the modeled
structure are notably shorter than those of TmPPase: The ATC
binding site is not present, as loop6–7 contributes about two-thirds
of the interface (table S3). This not only explains why ATC does not
inhibit PfPPase but also supports the notion that it functions
asymmetrically, preventing a full catalytic cycle from occurring by
binding to one chain and preventing the exit channel from opening.DISCUSSION
The first novel inhibitors of integral
membrane pyrophosphatases
mPPases are potential targets for anti-protozoan drug design as they do
not occur in humans and othermammals, are essential inT. brucei (24),
and render T. gondii noninfectious (19). Bisphosphonate derivatives
(PPi analogs) can inhibit mung bean mPPase (25) and prevent the pro-
liferation ofT. gondii (26) and other parasitic protists (27, 28). However,
they also inhibit human enzymes such as farnesyl pyrophosphate syn-
thase, so they are not viable as anti-parasitic drug candidates [for a re-
view, see (13)]. This study reports the first nonphosphorus inhibitors of
mPPase, which were identified through a screening process. The best
compound (ATC) binds and inhibits both the E2S and E2S2 complexes,
with inhibition constantsKi2obs andKi3obs of 1.37 and 3.18 mM, respec-
tively (Table 1). The overall IC50 is 1.7 mM. It appears to act in an al-
losteric manner. This mode of inhibition has been observed for an
inhibitor of soluble PPase fromMycobacterium tuberculosis (MtsPPase)
(29), but to our knowledge, this is the first one observed in mPPase.
Identification of alternate inhibitory mechanisms and
evidence for allostery in mPPases
ATC binds beside the exit channel (Figs. 2 and 3) and acts in alloste-
ric manner. Similar types of inhibition occur in GPCRs (G protein–
coupled receptors) and many other membrane proteins. For instance,
the voltage-dependent Kv11.1 (hERG) potassium channel that medi-
ates the repolarizing current in the cardiac action potential is easilyE  S
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Fig. 5. Substrate binding, hydrolysis, and inhibition at two active sites of a
dimeric TmPPase.Table 1. Kinetic parameters of TmPPase activity and ATC inhibition
constant.Kinetic parameter Valuekp 235 ± 28 μmol Pi mg
–1 min–1β 0.05 ± 0.005βkp 12.2 ± 1.03 μmol Pi mg
–1 min–1Ks 666 ± 110 μMα 0.12 ± 0.05αKs 80.7 ± 19.3 μMKI2obs 1.37 ± 0.09 μMKI3obs 3.18 ± 0.15 μM6 of 12
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 inhibited by a wide variety of drugs, leading to drug-induced longQT
syndrome and lethal arrhythmia. The molecules, such as quinolone
and macrolide antibiotics, bind to hydrophobic pockets on the side
of the selectivity filter (30, 31). Recently, a structural study found in-
hibitors that targeted a hitherto-unknown allosteric transmembrane site
in MsbA, an adenosine triphosphate (ATP)–binding cassette (ABC)
transporter, by locking MsbA in an inward facing conformation
that prevents transition to the outward-facing conformation during
lipopolysaccharide transport (32). This binding uncoupled the nucleotide-
binding domains, which adopt an asymmetrical conformation.
Similar interactions to the p-stacked ATC dimer that binds to
TmPPase have been observed in soluble protein-inhibitor complexes
as well. For example, Stornaiuolo et al. (33) found an isoquinoline
derivative that formed a p-stack of three identical molecules that
bound to one binding site of acetylcholine-binding protein. A quin-
azoline derivative formed a p-stack of five molecules to the lysine-
specific demethylase 1 (LSD1)–RE1-silencing transcription factor
corepressor (CoRESt) complex (34), and a phenylpyrrole derivative
forms a head-to-tail p-stacked dimer that binds in the twofold cavity
in soluble hexamericMtsPPase. This inhibitor appears to act uncom-
petitively with the binding site 20 Å from the nearest pyrophosphate
(29). The asymmetric binding of the ATC dimer to one monomer of
TmPPase is similar in kind.
A recent study has shown that mesophilic mPPases show substrate
inhibition with increased Km and decreased V when two molecules of
the substrate are bound in the presence of 50 mM K+ (23). Artukka
and co-workers (23) observed that S binds more weakly to E2S than to
E2 and that kcat for E2S2 is lower than for E2S. They interpreted this to
mean that substrate binding to onemonomer causes a conformational
change in the other that inhibits its interaction with the substrate. For
the enzymes they tested, the ratio of kcats varies between 2.9 and 16
[table 4 of Artukka et al. (23)]; our ratio is 20 (Table 1). However,
our data differ in that binding of the first substrate molecule appears
to be much weaker than that of the second substrate, as a is 0.12
(Table 1), which is the reverse of what they observed. There are twoVidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019possible explanations: First, they did not study TmPPase, but a range of
mesophilic K+-dependent mPPases. Second, and we think more likely,
our experiments are performed near the temperature optimum of
TmPPase (71°C) but in the presence ofn-dodecyl-b-D-maltopyranoside
(DDM), not of the bidentate membrane-spanning lipids found in
T. maritima (35). TmPPase inDDMmicelles is almost certainlymore
conformationally flexible than it is in T. maritima lipids, which would
weaken binding of the first substrate molecule. If, as both our and the
Artukka et al. (23) data suggest,mPPases are allosteric, then binding of
the first substrate molecule would stabilize the structure of the dimer,
increasing the affinity for the second substrate molecule and thus ex-
plaining the apparent discrepancy.
However, none of this is germane to the interpretation of the ATC
inhibition data. Our ATC-bound structure (Figs. 2 and 3) and inhi-
bition data (Fig. 4, D and E; Table 1; and table S6) are similar: An
ATC dimer is required to inhibit the TmPPase2:(Mg5PPi)1–2 dimer
in the presence of the substrate. The second site is unavailable in the
substrate-bound form, and neither monomer binds ATC before sub-
strate binds. At very low substrate concentrations (Fig. 4E and table
S6), the Hill coefficient is 3, suggesting that a third ATC is required to
inhibit the enzyme at concentrations below 100 mM, when the sub-
strate binds poorly in our assay.We suggest that this is also due to the
increased flexibility in DDM at 71°C: ATC binding can stabilize sub-
strate binding.
Correlation between functional and structural data
As the resolution of the structure is only 3.4 to 4.0 Å, how reliable is our
interpretation of the structure? The data were sufficient to identify K+ in
three of the four active sites. This is the first time that they have been
observed in a TmPPase structure: The electron density maps are signif-
icantly better than 4.0 Å. In addition, the POLDER analysis (fig. S1, K to
P) indicates that the ATC fit the density as expected at this resolution.
The link between the structural and functional data then rests on
two independent lines of evidence. First, the functional data are
consistent only with tight binding to the substrate-bound protein,A B
ATC-1
ATC-2
Loop8–9
(TMH8–9)
       1–2
(TMH6–7)
Loop12–13
(TMH12–13)
Fig. 6. The conservation of ATC binding site among mPPases. (A) Structure of TmPPase colored according to the sequence conservation among the set of 16 pathogenic
mPPases. Thepale green surface indicates the locationof theATCbinding site. (B) Comparison of theATCbinding sites of the crystal structure of TmPPase (wheat) andahomology
model of PfPPase (teal). Carbon atoms of ATC are presented as pale green sticks. Blue, nitrogen; red, oxygen; yellow, sulfur.7 of 12
SC I ENCE ADVANCES | R E S EARCH ART I C L E
 o
n
 June 17, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 and we could only obtain crystals with ATC bound in the presence of
IDP. Second, the functional data indicate that ATC binds as a dimer,
and this is what is observed. Close examination of the AB dimer in our
structure further reveals that there are more differences between the
two monomers than in any other TmPPase structure (table S4), particu-
larly in loop5–6 and loop12–13. It is possible that the changes we see are
due to crystal packing, not due to binding of ATC. However, as solution
data show that binding of ATC causes changes that prevent catalysis, we
suggest that these changes explain the lack of activity of the ATC-bound
enzyme. The alternative hypothesis is that binding of an ATC dimer be-
side the exit channel in a way that closes it and affects the TmPPase:IDP
dimer has nothing to do with observation of uncompetitive inhibition by
an ATC dimer in solution. Our suggestion that the crystal and solution
data are related is a more parsimonious explanation.
Mechanism of action of ATC
If our model is correct, then how does ATC inhibit TmPPase? The
binding of the dimer to chain A via loop6–7, loop8–9, and loop12–13
creates a hydrophobic clamp that locks the exit channel in the
closed state and TMH12 in the down state. The binding appears
to be driven by the multidentate interactions of Q268 with both
ATC-1 and ATC-2. We posit that the mechanistic implications of
these events are as follows. b1 extends from TMH6, which contains
D2436.50, D2466.53, and D2476.54, all of which coordinate Na+ in the
gate. In the ATC-bound structure, the position and coordination of
the Na+ change. In our current structure, D2466.53, D70316.46, and
Na+move up to 1.7 Å from their positions in the TmPPase:IDP struc-Vidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019ture (Fig. 1C). This corresponds to a new state that, we believe, keeps
the exit channel closed. Our currentmodel (10) posits that, during ion
pumping, TMH12 moves downward by at least 2 Å (9). Comparing
the relative positions of the ATC-bound and resting states suggests
that this movement of TMH12 makes loop12–13 move toward the
dimeric interface of the protein and TMH13 move “up” toward the
cytoplasmic side (Fig. 3D). This would induce equal conformational
changes in monomer B in TmPPase:IDP. However, ATC binding
locks monomer A TMH12 in the “down” state. Because of its “down”
position, loop12–13 and TMH13 can still trigger the conformational
changes of monomer B into a state that binds the substrate more
tightly. However, further catalysis is impossible because monomer B
cannot undergo a full catalytic cycle: The substrate can bind, but the
full motions required for catalysis are impossible. Diagnostic of these
motions is the conformation that leads to binding ofATC. In agreement
with the structure, the kinetic data show that ATC dimer only binds to
one of the monomers and bindsmost tightly to the TmPPase2(Mg5PPi)
state (Table 1).
The structure also explains substrate inhibition and the requirement
for potassium for maximal activity. The amino acid responsible for K+
dependency (A49512.46 in TmPPase) is located in TMH12, which is di-
rectly linked to the dimer interface (loop12–13 and TMH13). We sug-
gest that, in the presence of K+, the downward movement of TMH12
upon substrate binding and ion pumping induces conformational
changes in the monomer-monomer interface by the “away”movement
of loop12–13 and an upward movement of TMH13 (Fig. 3D). This is
then propagated to other TMHs. In the absence of K+, such couplingPP ATC2
6
12
13
Na+
No hydrolysis
TMH7
i
1–2
A B
CD
E
F
Fig. 7. Catalytic scheme of TmPPase and its inhibition by ATC. (A) The binding of the substrate (PPi; two joined red circles) to monomer A (wheat color) leads
to Na+ pumping (blue circle and blue arrow for the pumping direction) and induces a conformational change in monomer B (pink color). (B) This change
increases the affinity of monomer B for the substrate. The Na+ pumping causes substrate hydrolysis (yellow lightning symbol for this event) in monomer A,
while the substrate binding in monomer B leads to its Na+ pumping (C). (D) After hydrolysis, monomer A releases its hydrolysis products (2Pi; red circles), while
monomer B proceeds to the hydrolysis event, returning the enzyme to state A. The ATC dimer binds to its binding site after substrate binding and Na+ pumping
in monomer A (E), which locks this monomer in the “down” state. Although no hydrolysis can occur in monomer A due to the ATC binding, the conformational
change may still induce a conformational change in monomer B, which increases its affinity for the substrate (F). The numbering with white background
corresponds to TMH number.8 of 12
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 does not occur. These changes increase affinity and activity. They also
provide a possible structural explanation for the Na+/H+ pumping en-
zymes (23, 36), where H+ pumping is not inhibited by 100 mM Na+
and 50mMK+.Oneway thismight happen is through a conformation
similar to that observed here: The binding of PPi to monomer A and
pumping of, say, a proton would drive changes in loop12–13 and
TMH13 such that the conformation of monomer B became suitable
for binding PPi and pumping Na
+.
Revised catalytic model
In conclusion,we propose the followingmodel forTmPPase catalysis and
its inhibition by ATC (Fig. 7). Substrate binding to monomer A leads to
pumping inmonomerA and induces a conformational change inmono-
mer B, changing its affinity for PPi. After PPi binds in monomer B, PPi
hydrolysis occurs in monomer A and ion pumping in monomer B. The
product of catalysis (2Pi) is released from monomer A, allowing hydrol-
ysis and subsequent product release in monomer B. The ATC dimer can
only bindwhenPPi is bound tomonomerA.Nonetheless, theA:PPi form
can still induce the conformational change inmonomer B that allows PPi
binding. However, since the ATCbinding locksmonomerA in the down
state, no further catalysis can occur.
Our novel structure of TmPPase with IDP andATChas opened up
new routes to drug discovery of neglected diseases by serendipitously
demonstrating that there are alternative ways to inhibit mPPase. Al-
though the ATC binding interface is not preserved (Fig. 6 and fig. S8),
our data nevertheless indicate that binding at the exit channel can in-
hibit mPPases. The work shows how extracellular loop binding re-
gions can have significant effects on intracellular substrate binding
and vice versa. Last, by stabilizing asymmetric complexes, ATC pro-
vides a route into determining other steps along the reaction pathway
and thus deriving a full catalyticmodel—one thatmayunify theNa+/H+
and Na+ mPPases, as outlined above. o
n
 June 17, 2019
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Discovery of ATC and its analogs
The screening process that led to the discovery of compound 1 (ATC)
will be described inmore detail elsewhere. Briefly, we tested compounds
using a recently developed 96-well plate assay with TmPPase as amodel
system (37). The screening collections included compounds synthesized
in our laboratories. The identification of ATC as an inhibitor was fol-
lowed by the test of analogs 2 to 5. ATC and its analogs were initially
developed for their antimicrobial, antiviral, and anticancer activities, as
reported elsewhere (38).
Compound synthesis
The purity of all the compounds tested was above 95%. The synthesis of
ATC (compound 1) and compounds 2 to 5 has been described elsewhere
(38). The synthesis of compounds 6 to 9 is described in the Supplemen-
taryMaterials. For synthesis, all reactionswere carried out using commer-
cially available starting materials (Sigma-Aldrich, Schnelldorf, Germany;
BioFine International Inc., Vancouver, Canada; Fluorochem, Hadfield,
UK) and solvents without further purification. Column chromatography
was performed with an automated Isolera One high-performance flash
chromatography system (Biotage, Uppsala, Sweden) using a 0.1-mm
path length flow cell ultraviolet (UV) detector/recorder module (fixed
wavelength, 254 nm).Analytical thin-layer chromatographywas carried
out using 0.2-mm silica gel plates (silica gel 60, F254; Merck KGaA,
Darmstadt, Germany). NMR spectra (1H NMR and 13C NMR) wereVidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019recorded on a Bruker Ascend 400 spectrometer (Bruker Corporation,
Billerica, MA, USA). 1H NMR was measured at 400 MHz, and 13C
NMR was measured at 100 MHz. High-resolution mass spectra
(HRMS) were measured on a Waters Synapt G2 mass spectrometer
(Waters Corporation, Milford, MA, USA) and reported for the molec-
ular ions [M + H]+.
Protein expression and purification
Expression and purification of TmPPase are described elsewhere
(39, 40). In brief, His-tagged TmPPase in pRS1024 plasmid under
the control of the PMA1 promoter was freshly transformed into
Saccharomyces cerevisiae strain BJ1991. The cells were grown over-
night in 250 ml of selective synthetic complete dropout medium and
then added to 740ml of 1.5× YPmedium containing 2% glucose. The
cells were further grown at 30°C for 8 hours, collected by centrifuga-
tion (4000 rpm, 10 min), and lysed at 4°C using a bead beater with
0.2-mm glass beads. The membrane fraction was collected by ultra-
centrifugation (100,000g, 45 min), and the pellets were resuspended
in buffer containing 50 mMMES-NaOH (pH 6.5), 20% (v/v) glycerol,
50mMKCl, 5.2mMMgCl2, 1.33mMdithiothreitol (DTT), pepstatinA
[2 mg ml−1 (w/v)] (Sigma), and 0.334 mM phenylmethylsulfonyl flu-
oride (PMSF; Sigma). The membranes were solubilized using the
“hot-solve”method (40) at 75°C for 1.5 hours in solubilization buffer
[50 mM MES-NaOH (pH 6.5), 20% (v/v) glycerol, and 5.33% (w/v)
DDM (Anatrace)]. After centrifugation to remove denatured pro-
teins, KCl (to a final concentration of 0.3 M) and 2 ml of nickel–
nitrilotriacetic acid (Ni-NTA) beads (Qiagen) were added and incubated
at 40°C for 1.5 hours to each 40ml of the solubilized protein and then
loaded into an Econo-Pac column (Bio-Rad). Then, the column was
washed with 2 × CV (column volume) of washing buffer [50 mM
MES-NaOH (pH 6.5), 20% (v/v) glycerol, 50 mM KCl, 20 mM
imidazole (pH 6.5), 5 mMMgCl2, 1 mM DTT, pepstatin A (2 mg ml
−1,
w/v), 0.2 mM PMSF, and 0.05% DDM (Anatrace)] and eluted with
2 × CV of elution buffer [50 mMMES-NaOH (pH 6.5), 3.5% (v/v)
glycerol, 50 mM KCl, 400 mM imidazole (pH 6.5), 5 mM MgCl2,
1 mM DTT, pepstatin A (2 mg ml−1, w/v), 0.2 mM PMSF and 0.5%
octyl glucose neopentyl glycol (OGNPG; Anatrace), 1 mM DTT,
pepstatin A (2 mg ml−1, w/v), and 0.2 mM PMSF and 0.05% DDM
(Anatrace)].
Activity measurement and kinetic analysis
TmPPase activity, compound screening, and kinetic experiments
were done using themolybdenum blue reaction method in a purified
protein solubilized in DDM (37). Initial reaction rates of TmPPase
were determined using PPi as the substrate and ATC as the inhibitor
at varying concentrations. The concentration of MgCl2 and Na4PPi
required to maintain 5mM freeMg2+ at pH 8.0 was approximated as
described previously (41). The reaction was done in reaction buffer
[60mM tris-HCl (pH 8.0), 5mM freeMg2+, 100mMKCl, and 10mM
NaCl] at 71°C for 2 min. We chose a 2-min reaction time as it still
produces a reaction product in a linear range (fig. S7).
For analysis, we used a variant of Artukka and co-workers’method
(23), which assumes that the two active sites in an mPPase dimer in-
teract allosterically, with the addition of inhibitor binding to the two
active sites (Fig. 5). E2 represents the dimeric enzyme, S is the substrate
(Na4PPi), I is the inhibitor (ATC), and n is the number of ATC mol-
ecules bound to the enzyme. KS is a microscopic Michaelis-Menten
constant, and kp is the per-sitemaximum rate for the substrate complex.
a is the factor relating the binding of the first substrate molecule (KS) to9 of 12
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 the binding of the second, b is the factor relating the rate of hydrolysis of
the E2S complex (kp) to that of the E2S2 complex, andKI1obs,KI2obs, and
KI3obs are the observed inhibition constants for binding to the E2, E2S,
and E2S2 complexes.
For the mechanism in Fig. 5 with n = 2 (i.e., only inhibitor dimers
bind), the rate Eq. 1 (42) is
v ¼ ð2kp þ 2bkp½S=aKsÞ
2ð1þ ½I2=ðKI2obsÞ2Þ þ ðKs=½SÞð1þ ½I2=ðKI1obsÞ2Þ þ ð½S=aKsÞð1þ ½I2=ðKI3obsÞ2Þ
ð1Þ
where [S] and [I] correspond to substrate and inhibitor concentrations,
respectively, and the equilibrium andMichaelis-type constants are as in
Fig. 5. The kinetic data were fit together to obtain all parameter values
and their SEs by nonlinear regression as a function of inhibitor (0, 1.0,
2.0, 4.0, 8.0, and 12.0 mM) and substrate (0 to 1714 mM) concentrations
using Prism 6.0 (GraphPad Software). Eliminating theKI1 terms had no
effect on the overall quality of fit.
Crystallization, structure determination, and analysis
For crystallization, the purified protein was buffer-exchanged to the
crystallization buffer [50 mMMES-NaOH (pH 6.5), 3.5% (v/v) glyc-
erol, 50 mMKCl, 5 mMMgCl2, 2 mMDTT, and 0.5%OGNPG] on a
Micro Bio-Spin 6 column (Bio-Rad) and then diluted to a concen-
tration of 10 mg ml−1. Before crystallization, 1 mM IDP and 1 mM
ATC were added, and the solution was incubated on ice for 10 min
and centrifuged for 20 min (16,000g, 4°C). Crystallization trials were
done at 22°C by sitting-drop vapor diffusion method using commer-
cial screens, MemGold and PGA screen (Molecular Dimensions), in
MRC two-well crystallization plates (Swissci) with a mosquito robot
(TTP Labtech), and the drops were monitored using a minstrel DTUV
imaging system (Formulatrix). Crystal hits appeared in the MemGold
screen under different conditions. Crystallization conditions were then
optimized to get better crystals by varying pH, buffer, salt, and poly-
ethylene glycol (PEG) concentrations using the vapor diffusionmethod
in 1 ml + 1 ml (protein–mother liquor) drops in a 24-well plate at room
temperature. Harvestable crystals appeared within a week and were fro-
zen after soaking in cryoprotectant (mother liquor + 20% glycerol) or
directly frommother liquor. The best diffracting crystal appeared from
a solution containing 0.1 MMES (pH 6.5), 0.1 M NaCl, 33% PEG-400,
and 4% ethylene glycol.
X-ray diffraction data were collected at the European Synchro-
tron Radiation Facility, Grenoble (France), on the ID29 beamline
at 100 K on a PILATUS 6M detector. One thousand four hundred
images were collected at an oscillation angle of 0.1°. The data were
merged and scaled using X-ray Detector Software (XDS) (43). Be-
cause of the anisotropy of the diffraction data, anisotropic cutoff
and correction of the merged intensity data were performed on the
STARANISO server (http://staraniso.globalphasing.org/) using the
DEBYE and STARANISO programs. The structure was solved by
molecular replacement with Phaser (44) using the IDP-bound state
of the TmPPase structure (5LZQ) (10) as the search model. Phaser
found a unique solution in space group P212121, with four mono-
mers in the asymmetric unit forming two dimers. The structure
was built and refined using phenix.refine (45) and Coot (46). The
final model had Rwork/Rfree of 22.8%/28.4%, with 95.7% of residues in
the most favored and 4.3% in the allowed region of the Ramachandran
plot (table S1).
The structural interface and assembly of the protein were analyzed
using the PDBe PISA server (www.ebi.ac.uk/pdbe/pisa/) (47). InternalVidilaseris et al., Sci. Adv. 2019;5 : eaav7574 22 May 2019pocket analysis was done using the SplitPocket server (http://pocket.
med.wayne.edu/patch/) (48, 49). Structural alignments were done in
PyMOL with the default setting using the monomer structure, except
if stated differently. All structural figureswere produced using PyMOL
(https://pymol.org/2/).
Comparison with pathogenic mPPases
The sequences of TmPPase and 16 pathogenic mPPases were aligned
using Clustal Omega software (50), and conservation analysis was con-
ducted and visualized with the ConSurf server (51, 52) with default
parameters. The initial pairwise sequence alignment of TmPPase and
P. falciparum mPPase (VP1; PfPPase; sequence identity, 42%) was
produced with Discovery Studio 4.5 software (53) using the Align123
algorithm. The sequence alignment figure was generated with ESPript
3.0 (http://espript.ibcp.fr/ESPript/ESPript/index.php) (54). Homology
modeling was carried out with Modeller 9v14 (55) with default settings
in the Discovery Studio platform. The pairwise alignment was revised
during the course of model building; in total, nine models were con-
structed in three modeling rounds. The Modeller DOPE scores did
not differ significantly among these models, and a representative model
was selected to minimize strain in the loops connecting TMHs.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/5/eaav7574/DC1
Fig. S1. Electron density maps of ligands in the TmPPase:IDP:ATC structure.
Fig. S2. Asymmetric unit of TmPPase:IDP:ATC.
Fig. S3. Oligomerization state of TmPPase upon the addition of inhibitors.
Fig. S4. Comparison of the ATC binding sites in different TmPPase structures.
Fig. S5. Differences in the ATC binding site between monomers of the TmPPase:IDP:ATC
structure.
Fig. S6. Effect of ATC on growth of P. falciparum and on PfPPase.
Fig. S7. Linearity of TmPPase activity as a function of time and concentration.
Fig. S8. Multiple sequence alignment of mPPases from different organisms.
Scheme S1. Synthesis of analogs of 1 with heavy and basic atoms.
Table S1. X-ray data collection and refinement statistics.
Table S2. RMSD of TmPPase monomer in the asymmetric unit relative to monomer A.
Table S3. Major interactions of ATC with chains A and D.
Table S4. RMSD between chains A and B of loops in different TmPPase structures.
Table S5. RMSD of chain A of TmPPase:IDP:ATC loops to chain A of TmPPase:IDP loops.
Table S6. Hill constant of TmPPase inhibition by ATC at different substrate concentrations.
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